Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

BI 207127 for 5-days monotherapy.
(Poster 1862. L. Lagace, et al. Tue, November 2 - 7:00 AM. Hynes: Exhibit Hall C)


  • The Liver Kp Corrected Inhibitory Quotient (LCIQ): A pharmacokinetic-pharmacodynamic model for direct-acting HCV antivirals
    (Poster 1866. J. Duan, et al. Tue, November 2 – 7:00 AM. Hynes: Exhibit Hall C)About Hepatitis C Virus (HCV)HCV is an infectious disease of the liver and is a leading cause of chronic liver disease and liver transplant. The number of individuals chronically infected with HCV globally has been estimated at 170 million, with 3–4 million new infections occurring each year. Only about 20–45% of patients clear the virus in the acute phase. Of the remaining chronically infected patients, 20% will develop cirrhosis within a mean of 20 years. The mortality rate after cirrhosis has developed is 2-5% per year. End-stage liver disease due to HCV infection currently represents the major indication for liver transplantation in the Western world.

    About Boehringer Ingelheim in VirologyBoehringer Ingelheim has more than 6,900 scientists working in cross disciplinary teams within our global R&D network in six large therapeutic areas, including virology. In addition to its ongoing research program for HCV, Boehringer Ingelheim has a long-standing history in virology drug development, including compounds for the treatment of HIV. The company has a well established research center in Laval, Canada, dedicated to virology research since the early 1990's, and is committed to developing new therapies for virological diseases with a high unmet medical need.

    Boehringer Ingelheim in Hepatitis C Virus (HCV)BI 201335 is an investigational oral HCV NS3/4A protease inhibitor, discovered from Boehringer Ingelheim's own research and development, which has completed clinical trials through Phase IIb (SILEN-C studies). This Phase II program supports the investigation of BI 201335 in
    '/>"/>


  • SOURCE Boehringer Ingelheim Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
    3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    5. Tapestry Reports Second Quarter 2007 Results
    6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Corporation (OTC BB: SOTK) today announced sales of  $2,650,000 for ... of $2,202,000 for the prior year period, an increase of ... growth over the preceding quarter,s sales, continuing a trend that ... that experienced sales increases over the prior year were in ...
    (Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
    Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
    ... , , ATLANTA, Dec. 9 ... once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing ... dosing schedules. The data were among five studies that were ... Society (AES) in Seattle. , , ...
    ... for certain newly diagnosed patients with chronic myeloid leukemia , ... cells in 96% of Tasigna patients and reduction of abnormal CML protein ... Phase III trial evaluating Tasigna vs. Gleevec(R) now fully accrued , ... EAST HANOVER, N.J., Dec. 8 New results ...
    Cached Medicine Technology:New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 2New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 3New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 4New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 5New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 2Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 3Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 4Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 5Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 7Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 8Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 9Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 10Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 11Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 12Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 13
    (Date:7/11/2014)... Down is a reliable source for cheap Luke Bryan tickets ... years Luke Bryan has been honored by almost every major association ... award shows, but each summer, he hits the road on what ... and this summer is more of the same. When it comes ... success that is currently entitled to Luke Bryan. The native of ...
    (Date:7/11/2014)... (PRWEB) July 11, 2014 The ... NMR Spectroscopy, Chromatography, Electrophoresis, Surface Plasmon Resonance, X-ray ... Forecast to 2018", analyzes and studies the major ... Europe, Asia, and the Rest of the World ... growth in the past few years, mainly due ...
    (Date:7/11/2014)... July 11, 2014 Experience Mayan heritage ... Heritage Experience Package at the luxury all-inclusive AAA Five ... include a guided on-site ecological family tour where guests ... The Coba Mayan Encounter Tour at the Mayan archeological ... the tallest pyramid in the Yucatan and the only ...
    (Date:7/11/2014)... the distinguished wedding dress manufacturer and retailer, has recently ... . To top it all off, all these high ... to 65% off. Clients who place orders on the ... Fadhits.com is devoted to designing and selling beautiful wedding ... All its items come with very fast delivery. More ...
    (Date:7/11/2014)... 11, 2014 Emily Johnson, owner of the Portland ... fitness boot camp has held two charity workout events ... Saturday, July 26th, from 7:15 - 8:30 at Col Summers City ... charity boot camp session raised $510 for Medical Teams International. Their ... I Have a Dream. On July 26th, Johnson and Portland ...
    Breaking Medicine News(10 mins):Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3
    ... Feb. 15 (HealthDay News) -- Medical imaging tests are often ... new study suggests. The finding stems from a survey ... imaging tests conducted on 2,068 patients. The researchers found that ... called "defensive purposes" and accounted for about 35 percent of ...
    ... the "real world" may more effectively prevent cardiovascular ... findings in clinical research settings, according to the ... disease prevention guidelines for women., First published in ... based on findings observed in clinical research. That ...
    ... A mini exercise bike that can be used while working at ... others with sedentary jobs, according to a new study. The ... in front of most office chairs and used while a person ... 40 years old, on average. They spent at least 75 percent ...
    ... MONDAY, Feb. 14 (HealthDay News) -- Adults who experience hearing ... Alzheimer,s disease than those who don,t suffer hearing loss, new ... the risk, the study suggested. "This work suggests that ... an adult and the likelihood of developing cognitive decline with ...
    ... (HealthDay News) -- Heart disease patients are far more likely ... referral after discussing the matter with their doctor, a new ... and death by about 25 percent over one to two ... disease patients in Canada, the United States and United Kingdom ...
    ... HealthDay Reporter , MONDAY, Feb. 14 (HealthDay News) -- Most ... Administration for posing life-threatening or serious safety risks were initially ... approval process, new research reveals. The findings call out ... products from reaching the market in the first place, said ...
    Cached Medicine News:Health News:Fear of Lawsuits May Be Leading to Extra Medical Tests 2Health News:Updated heart disease prevention guidelines for women focus more on 'real-world' recommendations 2Health News:Updated heart disease prevention guidelines for women focus more on 'real-world' recommendations 3Health News:Study Suggests Hearing Loss-Dementia Link 2Health News:Study Suggests Hearing Loss-Dementia Link 3Health News:Too Few Heart Patients Go to Cardiac Rehab 2Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 2Health News:Report Blames Speedy FDA Clearance for Medical Device Recalls 3
    The Pneumatic Consulting Otoscope provides two viewing lenses for dual observation of the tympanic membrane. Sealed system for pneumnatic otoscopy and rotatable head for left- and right-sided viewin...
    Provides bright output and rotating lens with ultra-seal for pneumatic otoscopy....
    ... Cryotome FE and FSE are a new ... The microtome is outside of the cryochamber, ... well as faster temperature adjustment. Simple, multi-lingual ... temperature controls on the main touch-screen display. ...
    ... When it comes to laser treatment ... choroidal neovascularization,(CNV), nothing compares to the ... use with Visudyne (verteporfin for injection) ... wont find on any other laserfeatures,that ...
    Medicine Products: